Press releaseGlobe Newswire
Provectus Biopharmaceuticals
PVCT · OTC
$0.0499+$0.001 (+2.04%)TodayMarket closed ·
Prev close $0.0489
Latest news
- Press releaseGlobe Newswire
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
- Press releaseGlobe Newswire
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
- Press releaseGlobe Newswire
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
- Press releaseGlobe Newswire
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs
- Press releaseGlobe Newswire
Provectus Biopharmaceuticals Launches VisiRose, Provectus's Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.